Interview with Dr. Lou Vaickus, Tolerx, Question 6
DJ: Will there be any application of this drug class for Type 2 diabetes?
Advertisement
LV: Fascinating question! There have been very early studies to suggest that many of the problems that Type 2 diabetes patients have (increased heart disease and insulin resistance as examples) have their origin in an immune response in abdominal visceral adipose tissue that promotes inflammation and hence, damage to many organs. In one study in mice, an anti-CD3 antibody, given as a single treatment course for a short period of time (just like in Type 1 patients with otelixizumab), resulted in durable effects on insulin resistance. So, the answer here is ... stay tuned.
DISCLAIMER: The content of this Website is independent of the views of our advertisers and sponsors. The site is designed primarily for use by qualified physicians and other medical professionals. The information contained herein should NOT be used as a substitute for the advice of an appropriately qualified and licensed physician or other health care provider. The information provided here is for educational and informational purposes only. In no way should it be considered as offering medical advice. Please check with a physician if you suspect you are ill.
Copyright @ 1999-2013 Diabetes In Control, Inc.. All rights reserved.
